SAGE Therapeutics

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SAGE Therapeutics poised for Zuranolone launch in 2023, overcoming challenges

SAGE Therapeutics showcased strong financial performance and promising developments with Zuranolone, positioning the drug favorably for potential launch in 2023.
While facing challenges such as enrollment issues and DEA scheduling impacts, the company is leveraging opportunities in commercialization strategies and post-marketing studies to enhance Zuranolone's market presence.
Overall, Zuranolone's rapid and durable effects, alignment with current treatment practices, and targeted commercialization approach present a compelling opportunity for SAGE Therapeutics in the mental health treatment landscape.
By addressing challenges effectively and capitalizing on opportunities, SAGE Therapeutics is poised to make a significant impact in advancing treatments for mood disorders and improving patient outcomes.

Sage Therapeutics reports strong Q1 performance and eyes market expansion

Sage Therapeutics had a strong Q1 2023, focusing on brain health medicines and preparing for zuranolone's launch.
The company's financial position is solid, with growth opportunities in pipeline programs and proactive payer engagements.
Challenges include regulatory uncertainties and competition, but Sage is well-positioned to capitalize on market demand.
Opportunities lie in expanding product indications, proactive agreements with payers, and learning from competitors for strategic advantage.

SAGE Therapeutics to Launch Zurzuvae for Postpartum Depression, Overcomes FDA Setback

SAGE Therapeutics is poised to launch Zurzuvae for postpartum depression, leveraging its financial strength and clinical success. While facing challenges in MDD, the company is strategically adapting to focus on PPD and enhance operational efficiency. Opportunities lie in collaborations, pricing strategies, and addressing the significant market need for PPD treatments.

SAGE Therapeutics advances women's health with ZURZUVAE approval

SAGE Therapeutics navigates financial challenges while advancing innovative treatments for women's health.
ZURZUVAE's approval and commercialization plans present opportunities in a significant market segment.
Strategic focus on engagement, access, and market positioning key to ZURZUVAE's success.
Pipeline advancements and collaboration efforts position SAGE for future growth and impact.

SAGE Therapeutics excels with ZURZUVAE launch, poised for continued growth

SAGE Therapeutics had a strong performance in 2023, driven by the successful launch of ZURZUVAE and positive early market reception.
While facing challenges in data tracking and market competition, the company's focus on innovation and patient access presents growth opportunities.
With a robust pipeline and strategic initiatives in place, SAGE is well-positioned to maintain momentum and drive further success in the brain health space.

SAGE Therapeutics reports strong Zurzuvae launch amidst Parkinson's study setback

SAGE Therapeutics is navigating challenges from the PRECEDENT study while capitalizing on Zurzuvae's successful launch for PPD.
The company's pipeline progress and commitment to addressing cognitive disorders in neurodegenerative diseases showcase a strong focus on brain health.
Collaborative efforts with Biogen, strong payer coverage, and positive market feedback position Zurzuvae as a frontline treatment for PPD.
Strategic initiatives to educate prescribers, expand market reach, and refine study designs present promising growth opportunities for SAGE.

SAGE Therapeutics faces setbacks but sees success with ZURZUVAE in Q2

SAGE Therapeutics navigates setbacks with SAGE-324 study closure but sees success with ZURZUVAE in PPD treatment. Strong financial foundation and commitment to brain health initiatives position the company for future growth.

SAGE Therapeutics focuses on Zurzuvae for PPD treatment success

SAGE Therapeutics prioritizes Zurzuvae for PPD, showing strong revenue growth and prescription uptake
Challenges include discontinuation of certain programs and mixed results in clinical studies
Opportunities lie in focusing resources, upcoming study results, and strategic program ownership
Overall, SAGE's reorganization reflects a strategic shift towards maximizing Zurzuvae's potential

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Adagio Therapeutics

Allakos Inc

Alnylam Pharmaceuticals

argenx

BridgeBio Pharma Inc

Bicycle Therapeutics Plc - ADR

BioMarin Pharmaceutical

Denali Therapeutics

Incyte

Intra-Cellular Therapies

Jasper Therapeutics

Mirati Therapeutics

Praxis Precision Medicines

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

12 biotech stocks to consider buying now as prospects for the sector brighten this year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30am ET. A live webcast of the presentation can be accessed on the Investor page of Sage's website at investor.sagerx.com. A repl

Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022

Agios Pharmaceuticals

Enova Int.

Genworth Financial

Shenandoah Telecommunications

Smith & Wesson Brands

Bio-Rad Laboratories

eBay

Ironwood Pharma

Investors are keenly aware that growth stocks have beaten value stocks five years in a row. So what am I going to recommend today?

Robot Portfolio: Value in the Extreme

CRISPR Therapeutics

Novartis

The year 2021, was relatively mixed for biotech stocks with some posting significant gains while others pulled back dramatically. However, moving into 2022, we could see a significant rebound based on products launched in 2021, or in anticipation of new product announcements.

Top biotech stocks to watch in 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, will host its third annual “FutureCast: An R&D Portfolio Review” to showcase the Company's research and development strategy, and clinical progress in its depression, neurology, and neuropsychiatry franchise programs. “Sage's expertise in brain circui

Sage Therapeutics' Third Annual FutureCast Showcases Data from All Three Brain Health Franchises

Biogen

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE clinical program evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) presented at the American College of Neuropsychopharmacology (ACNP) Congress taking place December 5-8 in San Juan, Puerto Rico. Data from the SHORELINE and WATERFALL Studies in the LANDSCAPE clinical program further the understand

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone 50 mg once for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study. Related:   Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms.

Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months. The SHORELINE Study, part of the LANDSCAPE clinical program, was designed to naturalistically follow adult patients with major depressive disorder

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage FutureCast: An R&D and Portfolio Review on Tuesday, December 14 from 8:00 a.m. to 10:00 a.m. ET. Sage FutureCast will discuss the Company's research and development strategy, and clinical progress in programs throughout

Sage Therapeutics to Host Sage FutureCast Webcast

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1 at 8:30am ET. A live webcast of the fireside chat can be accessed on the Investor page of Sage's website at investor

Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 15 at 3:20pm ET. A live webcast of the fireside chat can be accessed on the Investor page of Sage's website at investor.sagerx.com.

Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

SAGE Therapeutics, Inc. (SAGE) CEO Barry Greene on Q3 2021 Results - Earnings Call Transcript

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -20.11% and -28.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the third quarter ended September 30, 2021. “I'm proud of the substantial progress we've made this quarter, including a successful pre-NDA meeting with the FDA for zuranolone. We're excited to have re

Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Sage Therapeutics (SAGE) Ahead of Earnings?

Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: Should You Buy?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Tuesday, November 2, 2021 at 8:00 a.m. ET to announce third quarter 2021 financial results and discuss recent business updates. The webcast can be accessed on the investor page of Sage's website at investor.sagerx.c

Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022. The planned initial submission package will seek approval of zuranolone for the treatment of major depressive disorder (MDD) and an additional filing for postpartum depression (PPD) is

Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022

Regeneron Pharmaceuticals

Royalty Pharma

With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a decline in their stock prices.

Top 3 undervalued US biotech stocks to buy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) and postpartum depression (PPD) presented at the 34th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 2-5, 2021. Presentations include data from the WATERFALL Study, a Phase 3

Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the launch of SageCitizen – a corporate social impact effort that activates and amplifies Sage's long-term commitment to People, Patients, Planet and Community. “At the core of our work at Sage is our mission to transform the lives of people with brain

Sage Therapeutics Launches SageCitizen Social Impact Initiative

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi as Chief Commercial Officer. In his new role, Mr. Benecchi will lead Sage's global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence. “Chris Benecchi is an innova

Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer

Sage Therapeutics (NASDAQ:SAGE) shares are trading higher after the company announced it received Fast Track Designation for SAGE-718 or the treatment of Huntington's disease. Sage Therapeutics is currently up 3.42% to a price of $45.09.

Why Sage Therapeutics Shares Are Trading Higher Today

SAGE Therapeutics Inc (NYSE:SAGE) is in the spotlight today, after the drugmaker received fast-track designation from the U.S. Food and Drug Administration (FDA) for its potential Huntington's disease treatment.

Biotech Stock Moves Higher After Fast-Track Designation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington's disease (HD). Fast Track is a process designed to facilitate the development and review of ne

News for SAGE Therapeutics Stock (SAGE)